Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × durvalumab × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 49 Gastrointestinal 27 Genitourinary 20 Head & Neck 14 Breast 14 Gynecologic 12 Other solid neoplasm 6 Sarcoma 4 Lymphoid 4 Plasma cell 3 Endocrine 3 Tumor-Agnostic 2 Other hematologic neoplasm 2 Dermatologic 2 CNS 2 NET 1 Myeloid 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 14 Octreotide 7 lanreotide 5 Sunitinib 5 Magnetic Resonance Spectroscopy 5 lutetium Lu 177 dotatate 4 pasireotide 3 gallium Ga 68 dotatate 3 cabozantinib 3 arginyllysine 3 Temozolomide 3 Specimen Handling 3 Nivolumab 3 Etoposide 3 Carboplatin 3 Bevacizumab 3 surufatinib 2 pembrolizumab 2 pazopanib 2 X-Rays 2 Phantoms, Imaging 2 Oxaliplatin 2 Ipilimumab 2 Erlotinib Hydrochloride 2 Doxorubicin 2 Cisplatin 2 Capecitabine 2 3-Iodobenzylguanidine 2 177Lu-DOTA-JR11 2 tremelimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03095274 2025-01-09

DUNE

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed

126 enrolled 18 charts

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡